Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA209196
Max Phase: Preclinical
Molecular Formula: C50H76N6O13
Molecular Weight: 969.19
Molecule Type: Small molecule
Associated Items:
ID: ALA209196
Max Phase: Preclinical
Molecular Formula: C50H76N6O13
Molecular Weight: 969.19
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O
Standard InChI: InChI=1S/C50H76N6O13/c1-6-8-9-10-11-12-13-14-15-16-20-23-40(60)54-43(32(4)57)49(67)55-42(31(3)7-2)47(65)56-44(33(5)58)48(66)52-37(28-34-21-18-17-19-22-34)45(63)51-38(30-41(61)62)46(64)53-39(50(68)69)29-35-24-26-36(59)27-25-35/h17-19,21-22,24-27,31-33,37-39,42-44,57-59H,6-16,20,23,28-30H2,1-5H3,(H,51,63)(H,52,66)(H,53,64)(H,54,60)(H,55,67)(H,56,65)(H,61,62)(H,68,69)/t31-,32+,33+,37-,38-,39-,42-,43-,44-/m0/s1
Standard InChI Key: RWQWKVVYXHQQLE-UMHICCRTSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 969.19 | Molecular Weight (Monoisotopic): 968.5470 | AlogP: 3.15 | #Rotatable Bonds: 34 |
Polar Surface Area: 309.89 | Molecular Species: ACID | HBA: 11 | HBD: 11 |
#RO5 Violations: 3 | HBA (Lipinski): 19 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.36 | CX Basic pKa: | CX LogP: 4.59 | CX LogD: -1.96 |
Aromatic Rings: 2 | Heavy Atoms: 69 | QED Weighted: 0.05 | Np Likeness Score: 0.22 |
1. Basse N, Papapostolou D, Pagano M, Reboud-Ravaux M, Bernard E, Felten AS, Vanderesse R.. (2006) Development of lipopeptides for inhibiting 20S proteasomes., 16 (12): [PMID:16630721] [10.1016/j.bmcl.2006.03.033] |
Source(1):